In the recent PAR008 release PAR management claimed that there was not just cartilage preservation but growth. This is unheard of in any OA medication study.
So why is there a lack of scientific or media interest?
Why is there a lack of exuberance in the AGM on this point?
Why is there an increase in short interest?
Why would non-executive directors leave?
Why the lack of peer review that has always been promised, for a number of years?
If the claim is....then why ?
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.010(4.08%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 23.0¢ | $115.0K | 467.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 62741 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 537 | 4 |
View Market Depth
| Last trade - 13.00pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
24.0¢ |
Change
-0.010 ( 4.00 %) |
||||
| Open | High | Low | Volume | ||
| 25.0¢ | 26.0¢ | 23.0¢ | 330077 | ||
| Last updated 13.26pm 06/05/2024 ? | |||||
| PAR (ASX) Chart |